T 1179/23 (Compositions of dabigatran etexilate / TOWA PHARMACEUTICAL) vom 14.01.2026
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2026:T117923.20260114
- Datum der Entscheidung
- 14. Januar 2026
- Aktenzeichen
- T 1179/23
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 13704974.8
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN ETEXILATE
- Name des Antragstellers
- TOWA PHARMACEUTICAL EUROPE, S.L.
- Name des Einsprechenden
- Aera A/S
Hamm&Wittkopp Patentanwälte PartmbB - Kammer
- 3.3.07
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 123(2)European Patent Convention Art 56European Patent Convention R 139Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 012(6)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Schlagwörter
- Late-filed evidence - admittance in appeal proceedings (yes)
Requests filed during appeal proceedings - admitted (yes)
Request for continuation in writing - rejected
Validity of priority date (yes)
Amendments - correction of obvious errors (no)
Inventive step - main request and auxiliary requests 1 and 2 (no), auxiliary requests 3 and 15 (yes) - Orientierungssatz
- -
- Zitierende Akten
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside.
The case is remitted to the opposition division with the order to maintain the patent in amended form on the basis of claims 1 to 6 of auxiliary request 3 filed with the reply to the appeals, paragraph [0088] of the description filed with the reply to the appeals, and the further paragraphs of the description to be adapted.